

## THE PRESENT AND FUTURE

### STATE-OF-THE-ART REVIEW

# Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction



Robert J. Mentz, MD,\* Jacob P. Kelly, MD,\* Thomas G. von Lueder, MD, PhD,† Adriaan A. Voors, MD,‡ Carolyn S.P. Lam, MBBS,§ Martin R. Cowie, MD, MSc,|| Keld Kjeldsen, MD, DSc,¶ Ewa A. Jankowska, MD, PhD,# Dan Atar, MD, PhD,† Javed Butler, MD, MPH,\*\* Mona Fiuzat, PHARM D,\* Faiez Zannad, MD,†† Bertram Pitt, MD,‡‡ Christopher M. O'Connor, MD\*

#### ABSTRACT

Heart failure patients are classified by ejection fraction (EF) into distinct groups: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF). Although patients with heart failure commonly have multiple comorbidities that complicate management and may adversely affect outcomes, their role in the HFpEF and HFrEF groups is not well-characterized. This review summarizes the role of noncardiac comorbidities in patients with HFpEF versus HFrEF, emphasizing prevalence, underlying pathophysiologic mechanisms, and outcomes. Pulmonary disease, diabetes mellitus, anemia, and obesity tend to be more prevalent in HFpEF patients, but renal disease and sleep-disordered breathing burdens are similar. These comorbidities similarly increase morbidity and mortality risk in HFpEF and HFrEF patients. Common pathophysiologic mechanisms include systemic and endomyocardial inflammation with fibrosis. We also discuss implications for clinical care and future HF clinical trial design. The basis for this review was discussions between scientists, clinical trialists, and regulatory representatives at the 10th Global CardioVascular Clinical Trialists Forum. (J Am Coll Cardiol 2014;64:2281-93) © 2014 by the American College of Cardiology Foundation.

From the \*Duke University, Durham, North Carolina; †Oslo University Hospital Ullevål, University of Oslo, and Institute of Clinical Sciences, University of Oslo, Oslo, Norway; ‡University of Groningen, Groningen, the Netherlands; §Framingham Heart Study, Framingham, Boston University School of Medicine, Boston, Massachusetts; ||National Heart and Lung Institute, Imperial College and Imperial College London, Royal Brompton Hospital, London, United Kingdom; ¶Copenhagen University Hospital (Rigshospitalet), Copenhagen, and Aalborg University, Aalborg, Denmark; #Department of Heart Diseases, Wrocław Medical University, Wrocław, Poland; \*\*Emory University, Atlanta, Georgia; ††INSERM, Centre d'Investigations Cliniques, Université de Lorraine and CHU de Nancy, Nancy, France; and the ‡‡University of Michigan School of Medicine, Ann Arbor, Michigan. Dr. Mentz has received research support from Gilead Sciences, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Otsuka, Amgen, and ResMed; and honoraria from Thoratec. Dr. Mentz was supported by the National Institute of General Medical Sciences (grant T32GM086330). Dr. Cowie is a member of the speakers bureau for Pfizer Inc., Bayer HealthCare, Novartis, Servier, ResMed, Medtronic, Boston Scientific, and St. Jude Medical. Dr. Cowie is supported by the National Institute for Health Research Cardiovascular Biomedical Research Unit at the Royal Brompton Hospital. Dr. Voors received consultancy fees and/or research grants from Alere, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Cardio3Biosciences, Celladon, Johnson and Johnson, Merck/MSD, Novartis, Servier, Torrent, Trevena, and Vifor. Dr. Butler has served as a consultant to Amgen, BG Medicine, Celladon, Gambro, Ono Pharma, Trevena, Takada, Bayer HealthCare, Medtronic, CardioCell, Novartis, and GE Healthcare; and has received research support from the National Institutes of Health, European Union, and the Health Resources and Services Administration. Dr. Jankowska has received honoraria from Vifor Pharma; and an unrestricted grant for Wrocław Medical University. Dr. Atar has received consultancy honoraria from Novartis, Pfizer Inc., Vifor Pharma, and Bayer Healthcare. Drs. Fiuzat and O'Connor have received research support from ResMed. Dr. Pitt has received consultancy fees and/or stock options from Pfizer Inc., Bayer HealthCare, Lilly, Stealth Peptides, SC Pharmaceuticals, Sarfex Pharmaceuticals, and Relysa. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

[Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.](#)

[You can also listen to this issue's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.](#)

Manuscript received April 26, 2014; revised manuscript received August 19, 2014, accepted August 28, 2014.



## ABBREVIATIONS AND ACRONYMS

**COPD** = chronic obstructive pulmonary disease

**CPAP** = continuous positive airway pressure

**CSA** = central sleep apnea

**DM** = diabetes mellitus

**EF** = ejection fraction

**HFpEF** = heart failure with preserved ejection fraction

**HFrEF** = heart failure with reduced ejection fraction

**LV** = left ventricular

**OSA** = obstructive sleep apnea

**RAAS** = renin-angiotensin-aldosterone systems

**SDB** = sleep-disordered breathing

Patients with heart failure (HF) often have multiple concomitant diseases that complicate management and may adversely affect outcomes (1,2). Recent data from the Centers for Medicare & Medicaid Services demonstrate that 55% of Medicare patients coded as having HF have  $\geq 5$  chronic comorbidities (3). Data from the European Society of Cardiology Heart Failure Pilot Survey indicate that the majority of patients with chronic HF (74%) had at least 1 comorbidity, the most common of which are renal disease, anemia, and diabetes mellitus (DM) (4). In general, more than one-quarter of HF patients have comorbid pulmonary or renal dysfunction, both of which are associated with increased morbidity and mortality in the overall HF population (5-8). Patients are commonly classified

according to ejection fraction (EF) into heart failure with preserved ejection fraction (HFpEF) (EF  $\geq 50\%$ ) or heart failure with reduced ejection fraction (HFrEF) (EF  $< 50\%$ ). The role of comorbidities has not been well characterized in these HF types. The present review summarizes the role of noncardiac comorbidities in patients with HFpEF versus HFrEF, with particular emphasis on prevalence, underlying pathophysiological mechanisms, and association with outcomes. We focused on chronic obstructive pulmonary disease (COPD), anemia, DM, renal disease, sleep-disordered breathing (SDB), and obesity. We briefly discuss other noncardiac comorbidities, including frailty and arthritis, and highlight the need for future research on these topics, as well as on depression, myopathy, and liver disease. The implications of these data for clinical care and for the design of future HF clinical trials are also described. Cardiac comorbidities (including hypertension, coronary artery disease, and atrial fibrillation) were recently discussed elsewhere (9) and are beyond the scope of the present review. This review is on the basis of discussions between scientists, clinical trialists, and regulatory and industry representatives at the 10th Global CardioVascular Clinical Trialists Forum held in Paris, France, on December 6, 2013.

## METHODS

To identify additional relevant published data not discussed at the 10th Global CardioVascular Clinical Trialists, we searched MEDLINE (via PubMed) from January 1994 to July 2014 (the Online Appendix presents the full search strategy). We used Medical Subject Headings and key words, focusing on the

most relevant terms for this topic. We manually searched reference lists of pertinent reviews, including studies and background data to find any relevant citations that our searches might have missed. We imported all citations into an EndNote X7 database. One reviewer (J.P.K.) screened and evaluated the retrieved records to select relevant studies. To focus on studies with representative patient samples, our search strategy required that publications included  $> 500$  patients and reported data from multiple sites. Given that entry criteria for clinical trials tend to exclude those with significant comorbidities, we focused on data from large HF registries and cohort studies. We required that the primary papers or supplemental materials include data on noncardiac comorbidities of interest.

In general, the prevalence of comorbidities was high across all studies, as demonstrated in the 3 largest U.S. HF registries (2,10,11), as well as ambulatory HF populations in the United States (12,13), as discussed later in this review. Other world regions demonstrated findings similar to those seen in the United States (14-16). Table 1 presents comorbidity prevalence data from several representative HF registries and epidemiological cohorts.

## RESULTS

### HFPEF VERSUS HFREF: DEMOGRAPHIC DIFFERENCES.

Overall, the data suggest that patients hospitalized with HFpEF tend to be 4 to 8 years older than those with HFrEF and are more often female (Table 1). These observations are supported by an analysis from the Framingham Heart Study, which demonstrated that female sex was independently associated with a  $> 2$ -fold increased risk for HFpEF versus HFrEF (17). Increasing age predicts both HFpEF and HFrEF, but the risk is significantly greater for HFpEF (18). The sex differences in HF phenotype seem largely due to increased HFrEF in men related to previous myocardial infarction (18). Another explanation for these findings relates to a differential response to hypertension in men versus women. Men tend to develop eccentric left ventricular (LV) hypertrophy in response to hypertension, whereas women tend to develop concentric LV hypertrophy (19). Studies also found that African-American subjects have HFpEF less often than they have HFrEF (2,10,11). These findings are counterintuitive due to the high prevalence of hypertension and LV hypertrophy in this population. The specific reasons for these observations are unknown and require further investigation, but they may be related, in part, to ascertainment of the HFpEF diagnosis. It is unclear whether these findings are due

to increased complexity in HFpEF detection, particularly in regions where echocardiography or natriuretic peptides are less available. In general, there is a relative paucity of large-scale comparative data regarding the burden of comorbidities in racial and ethnic minority populations with HF (20).

**OUTCOMES OVERVIEW.** Evidence regarding the outcomes of HFpEF versus HFrEF patients varied in different populations, but overall, the data suggest that HFpEF is associated with substantial morbidity and mortality that approaches or matches that of HFrEF (13,21,22). Interestingly, 1 recent analysis demonstrated that when similar B-type natriuretic peptide levels were compared across EF values, the risk for adverse outcomes was similar in HFpEF and HFrEF patients (23). The overall incidence of hospital admission is similar between the 2 groups, but HFpEF patients have a higher incidence of non-HF hospitalizations, whereas HFrEF patients have a higher incidence of HF hospitalizations (24). Comorbidities, such as COPD, renal disease, and DM, are strongly associated with adverse outcomes in HF patients (25). HFpEF is not merely a disease of old age and multiple comorbidities but is a distinct entity associated with poor prognosis and severe cardiovascular dysfunction (26,27). However, few studies have explored the differential association between comorbidities and outcomes in HFrEF and HFpEF patients (24,28-30). In general, the increased risk for morbidity and mortality associated with these comorbidities is similar in those with HFpEF and HFrEF.

**PATHOPHYSIOLOGY.** The **Central Illustration** presents pathways linking several comorbidities to disease progression in both HFpEF and HFrEF. These comorbidities interrelate by several common mechanisms, including inflammation and activation of the sympathetic and renin-angiotensin-aldosterone systems (RAAS), as discussed later in this review.

**COMORBIDITIES IN HFrEF VERSUS HFpEF PATIENTS: PREVALENCE, OUTCOMES, AND TREATMENTS. Chronic obstructive pulmonary disease.** COPD occurs in approximately one-third of HF patients, with a slightly higher prevalence in HFpEF patients compared with HFrEF patients (5); the specific rationale for the increased prevalence in HFpEF patients is unclear. Comorbidities such as COPD were suggested to induce a proinflammatory state that causes endothelial and cardiomyocyte dysfunction, with resultant myocardial fibrosis and clinical HFpEF (31). Ongoing smoking was also identified as an independent predictor of HFpEF, but not HFrEF, in epidemiological studies (18), which supports the inflammatory hypothesis. However, further research is

**TABLE 1** Demographic Characteristics and Prevalence of Noncardiovascular Comorbidities in Patients With Acute HF

	ADHERE Registry (2)		OPTIMIZE-HF Registry (10)		GWTG Registry (11)*		Ather et al. (24)		Olmsted County 1987-2001		Olmsted County 2003-2005	
	Reduced (n = 25,865) 50%	Preserved (n = 26,322) 50%	LVSD (n = 20,118) 49%	Preserved (n = 21,149) 51%	EF <40% (n = 55,083) 50%	EF ≥50% (n = 40,354) 36%	Reduced (n = 6,599) 70%	Preserved (n = 2843) 30%	Reduced (n = 2,429) 53%	Preserved (n = 2167) 47%	Reduced (n = 248) 45%	Preserved (n = 308) 55%
	Acute HF, 274 Hospitals*, 2001-2004		Acute HF, 259 Hospitals, 2003-2004		Acute HF, 275 Hospitals, 2005-2010		Ambulatory HF, U.S. Veterans, 2000-2002		Acute HF, 1987-2001		Inpatients and Outpatients With HF	
Age, yrs	70 ± 14	74 ± 13	70 ± 14	75 ± 13	70 (58-80)	78 (67-85)	70 ± 10	71 ± 10	72 ± 12	74 ± 14	73 ± 14	77 ± 13
Female	40%	62%	38%	62%	36%	63%	4%	9%	35%	56%	42%	57%
African-American race	22%	17%	21%	15%	25%	16%	13%	10%	-	-	-	-
Medical history												
COPD or asthma	27%	31%	-	-	27%	33%	27%	34%	-	-	30%	38%
Renal insufficiency	26%	26%	-	-	48%	52%	52%	49%	-	-	-	-
Anemia	-	-	-	-	14%	22%	28%	33%	-	-	49%	53%
Diabetes mellitus	40%	45%	24% noninsulin/15% insulin	26% noninsulin/17% insulin	22% oral therapy/18% insulin	24% oral therapy/22% insulin	40%	45%	34%	33%	38%	36%
Obesity (%) or body weight, kg	-	-	78.5 (65.8-94.0)	78.9 (64.0-97.5)	25%	33%	35%	51%	36%	41%	-	-
Laboratory data												
BMI, kg/m <sup>2</sup>	-	-	-	-	-	-	-	-	28.6 ± 7.0	29.7 ± 7.8	29.1 ± 7.8	29.6 ± 7.5
Hemoglobin, g/dl	-	-	12.5 ± 2.0	11.9 ± 2.0	12.4 (11-13.8)	11.5 (10.2-12.9)	-	-	12.5 ± 2.0	11.8 ± 2.1	-	-
Creatinine, mg/dL	1.6 ± 1.3	1.7 ± 1.5	1.4 (1.1-1.9)	1.3 (1.0-1.8)	1.3 (1-1.8)	1.3 (1-1.9)	-	-	1.6 ± 1.0	1.6 ± 1.1	-	-

Values are mean ± SD, median (interquartile range), or %. \*A total of 274 hospitals included in the analysis cited. †Patients with an LVEF between 40% and 49% were excluded from this table.

ADHERE = Acute Decompensated Heart Failure National Registry; BMI = body mass index; COPD = chronic obstructive pulmonary disease; EF = ejection fraction; GWTG = Get With The Guidelines; HF = heart failure; LVSD = left ventricular systolic dysfunction; OPTIMIZE-HF = Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure.

COMORBIDITY	BIDIRECTIONAL IMPACT ON DISEASE PROGRESSION	HEART FAILURE SPECIFICS
Chronic obstructive pulmonary disease	Inflammation; hypoxia; parenchymal changes; airflow limitation, leading to pulmonary congestion; abnormal left ventricular (LV) diastolic filling; inhaled beta-agonist cardiovascular effects Elevated LV end-diastolic pressure and beta-blocker use may compromise lung function	More prevalent in preserved ejection fraction (HFpEF), compared to reduced (HFrEF) Higher mortality risk in HFpEF
Anemia	Adverse LV remodeling; adverse cardiorenal effects; increased neurohormonal and inflammatory cytokines Inflammation; hemodilution; renal dysfunction; metabolic abnormalities exacerbate	More prevalent in HFpEF Similar increased risk for mortality in both groups
Diabetes	Diabetic cardiomyopathy; mitochondrial dysfunction; abnormal calcium homeostasis; oxidative stress; renin-angiotensin-aldosterone system (RAAS) activation; atherosclerosis; coronary artery disease Incident and worsening diabetes mellitus via sympathetic and RAAS activation	More prevalent in HFpEF Similar increased risk for mortality in both groups
Renal dysfunction	Sodium and fluid retention; anemia; inflammation; RAAS and sympathetic activation Cardiorenal syndrome through low cardiac output; accelerated atherosclerosis; inflammation; increased venous pressure	Similar prevalence in both groups Similar increased risk for mortality in both groups
Sleep-disordered breathing	Hypoxia; systemic inflammation; sympathetic activation; arrhythmias; hypertension (pulmonary and systemic); RV dysfunction; worsening congestion Rostral fluid movement may worsen pharyngeal obstruction; instability of ventilatory control system	Similar prevalence in both groups Unknown mortality differential associated with HFpEF vs. HFrEF
Obesity	Inflammation; reduced physical activity and deconditioning; hypertension; metabolic syndrome; diabetes mellitus Fatigue and dyspnea may limit activity; spectrum of metabolic disorders including nutritional deficiencies	More prevalent in HFpEF Obesity paradox; potential for a U-shaped association with mortality

Mentz, R.J. et al. J Am Coll Cardiol. 2014; 64(21):2281-93.

#### CENTRAL ILLUSTRATION Associations Between HFpEF and HFrEF, With Comorbidities

Pathways linking several common comorbidities to disease progression in both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) are presented, and factors exacerbating other comorbid conditions are highlighted. These comorbidities are interrelated by several common mechanisms, including inflammation and worsening congestion, as well as by sympathetic and renin-angiotensin-aldosterone system activation. Heart failure influences each of the comorbidities, demonstrating the bidirectional association. CV = cardiovascular; LV = left ventricular; RAAS = renin-angiotensin-aldosterone system; RV = right ventricular.

needed because smoking would also be expected to increase risk for coronary events and resultant ischemic cardiomyopathy with reduced EF. An alternative explanation for the close association between COPD and HFpEF involves coupling between impaired LV filling and pulmonary venous changes due to lung parenchymal abnormalities (32). Moreover, HF may result in pulmonary function changes and patient symptoms that mimic COPD. Because patients with preserved EF do not have the alternative diagnosis of low EF, they may be more likely to receive a COPD diagnosis as an explanation for dyspnea (33,34). Despite the potential for bias related to increased COPD diagnosis in HFpEF patients, the consistent observation of increased COPD prevalence in HFpEF patients suggests that concomitant pulmonary and cardiac dysfunction may be particularly important in the preserved EF group.

The primary effect of COPD seems to be increased noncardiovascular mortality during HF hospitalization (6), with similar outcomes in the early period after discharge (35). COPD is associated with increased long-term morbidity (36) and mortality (25). HF patients with COPD are less likely to receive beta-blockers compared with those without COPD (36), possibly due to clinicians' concerns about precipitating bronchoconstriction (33,37,38). The overlapping symptom of dyspnea with both diseases may lead to misapplication of therapy. Given the discordant beta-receptor effects of the different disease treatments, a patient's symptoms and outcome could be adversely affected by the treatment of the comorbid disease. HF patients with COPD also tend to have lower blood pressure, higher creatinine levels, and underuse of angiotensin-converting enzyme inhibitors and mineralocorticoid receptor antagonists

(6,35). These characteristics likely contribute to the increased mortality risk associated with COPD in patients with HF.

In a recent analysis of the differential association between comorbidities and outcomes in HFrEF and HFpEF patients, COPD was the only comorbidity for which there was a significant interaction ( $p = 0.01$ ) with EF group and outcomes. COPD contributed to a higher hazard for mortality in patients with HFpEF compared with HFrEF (24). Notably, COPD was an independent predictor of mortality in both groups. These between-group differences are supported by findings from another small study in which COPD was highly predictive of death in those with HFpEF but not HFrEF (39). Data from the Framingham Heart Study support a potential causal role between airflow limitation and HFpEF but not HFrEF (40). The link between even mild airflow limitation and abnormal LV diastolic filling (41) may explain, in part, the stronger association between COPD and HFpEF.

COPD treatment recommendations focus on prevention, including vaccinations and smoking cessation. Pending randomized trial data, chronic therapy with long-acting anticholinergic agents is recommended preferentially over the use of inhaled beta-agonists (37). Early intervention in the setting of exacerbations and a multidisciplinary approach may be indicated to balance therapies for both diseases (33). Intravascular volume management may represent an area of particular focus, with the goal of minimizing LV filling pressures and pulmonary interstitial fluid, even in the presence of agents that adversely affect volume status, such as corticosteroids. With respect to beta-blocker use, there is a mechanistic rationale to consider the preferential use of cardioselective agents, such as metoprolol succinate or bisoprolol, rather than carvedilol (37). Evidence from several small studies supports this approach (38,42,43). However, observational studies suggested that there is no differential benefit with cardioselective agents compared with noncardioselective agents (36,44). Thus, adequately powered prospective studies are needed to determine the optimal beta-blocker approach in HF patients with COPD.

**Anemia.** Comorbid anemia is more frequent in HFpEF patients than in HFrEF patients. Prevalence reports vary depending on the specific anemia definition used, but the trends are comparable. Contemporary studies tend to use the World Health Organization classification of anemia as hemoglobin  $<13$  g/dl in men and  $<12$  g/dl in women (24). In the Get With The Guidelines Registry, there was an association between higher EF and increased prevalence of anemia (11). The prevalence of anemia was 22% in

patients with an EF  $\geq 50\%$ , 20% with EF 40% to 49%, and 14% with EF  $<40\%$ , and there were also sex-specific differences (45). The prevalence of anemia tended to be higher in women in the setting of either reduced or preserved EF. These findings are supported by an analysis from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Patients with Heart Failure), which showed that HF patients (46) with low hemoglobin levels were older, more often female, and had preserved systolic function. In the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program, lower hemoglobin was associated with higher EF (47). Furthermore, female sex, DM, and worse renal function were several of the strongest predictors of anemia. These findings suggest a complex relationship between EF and anemia that likely involves inflammation, hemodilution, bone marrow deficiency, nutritional and metabolic factors, and nephropathy (48). In addition, studies suggest that anemia may increase cardiac output and reduce systemic resistance through nitric oxide-mediated vasodilation (49-51).

Anemia is associated with increased morbidity and mortality in HF patients (52-55). Potential explanations include adverse LV remodeling effects (56), increased neurohormonal and inflammatory cytokines (49), adverse cardiorenal effects (57), and the association with poor nutritional status (47). Multiple previous studies have reported that there is no interaction between EF and outcomes related to anemia status. For instance, in 1 study, anemia was associated with an  $\sim 25\%$  increased mortality risk in HFrEF and HFpEF patients (24). Similarly, Felker *et al.* (28) demonstrated that anemia was independently associated with mortality, and there was no evidence of an interaction with systolic function. A recent analysis from the SENIORS (Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure) trial, which included HF patients irrespective of LVEF, extends these results to morbidity endpoints (58). Anemic patients were at increased risk for the composite of all-cause mortality or cardiovascular hospitalization and mortality, or HF hospitalization, regardless of underlying HFrEF or HFpEF. Notably, the overall representation of patients with LVEF  $>50\%$  in SENIORS was modest. The inability to demonstrate a differential relationship between anemia and outcomes in those with HFpEF versus HFrEF may be related, in part, to the number of different etiologies for anemia.

Because of the neutral results of recent trials targeting anemia with erythropoietin-stimulating agents in HFrEF patients (59), the optimal treatment of



underlying anemia in HF requires further study. Given iron deficiency's relation to anemia status and its potential as a treatable target, this area is of particular interest (60). The prevalence of iron deficiency in HF patients is even greater than the prevalence of clinical anemia. Furthermore, iron deficiency may affect outcomes in HFpEF and HFrEF independent of anemia (61). Iron deficiency leads to worsening HF symptoms, HF progression, and poor outcomes (62). Ongoing and future studies will explore the effect of iron replacement in both HFpEF and HFrEF patients.

**Diabetes mellitus.** Registry and observational data consistently report the presence of DM in ~40% of HFrEF patients versus 45% of HFpEF patients (2,10,24). DM is associated with the development of myocardial dysfunction, even in the absence of significant coronary artery disease or hypertension (i.e., diabetic cardiomyopathy) (63). Myocardial changes result from insulin resistance and hyperglycemia through various mechanisms, including increased free fatty acid concentration, mitochondrial dysfunction, abnormal calcium homeostasis, RAAS activation, oxidative stress, and advanced glycation end products (63,64). Development of systolic dysfunction may be preceded by myocardial fibrosis and collagen deposition, resulting in diastolic dysfunction (65,66). Importantly, the relationship between DM and HF seems bidirectional, with HF also increasing the risk for subsequent DM (67). The mechanisms underlying the effect of HF on incident DM or on DM progression are not completely known, but they may involve sympathetic and RAAS activation, with subsequent lipolysis and increased cytokine production (68,69).

DM is associated with increased morbidity and mortality in patients with chronic HF (29,70), but its influence as a predictor of long-term outcomes after HF hospitalization is less well defined. Several acute HF registries have suggested that DM patients are at increased risk for mortality (71,72). However, in the OPTIMIZE-HF registry, DM patients were at increased short-term risk for rehospitalization but at similar risk for in-hospital and short-term mortality (73). Similarly, in the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) study, DM was associated with increased HF rehospitalization but not with all-cause mortality (74). DM may complicate the clinical course of HF patients through various mechanisms, including electrolyte disturbances, increased infection risk, and altered medication absorption, as well as through ischemia and other direct adverse effects on the myocardium (1).

The impact of DM in patients with HFpEF versus HFrEF is not well defined. One recent analysis demonstrated that the point estimate of hazard for mortality associated with DM was greater in HFrEF patients than in HFpEF patients, but formal statistical testing did not find an interaction between the DM and EF groups (24). An analysis from CHARM demonstrated that DM was associated with similarly increased risk for mortality in HFpEF and HFrEF patients (29). In contrast, DM was associated with increased cardiovascular death or HF hospitalization in HFpEF patients compared with HFrEF patients. This difference was due to an increased risk for HF hospitalization associated with DM in HFpEF patients. However, in an analysis from OPTIMIZE-HF, HFpEF patients with DM were not at increased risk for 60- to 90-day mortality or rehospitalization, in contrast to the increased risk associated with DM in HFrEF patients (interaction  $p = 0.0012$ ) (73). Thus, the impact of DM on outcomes in different EF groups is not entirely clear, but it may be related to predominant effects on long-term HF rehospitalization, rather than mortality. It is also possible that there are differential effects in patients who had a recent HF hospitalization compared with those who have chronic, stable HF.

The optimal treatment of comorbid diabetes in HF patients is unclear. Several classes of antidiabetic agents such as thiazolidinediones and dipeptidyl peptidase 4 inhibitors were shown to be associated with increased risk of HF (75,76). Alternatively, ongoing studies are investigating whether antidiabetic agents, such as glucagon-like peptide-1 agonists, may improve outcomes in HF patients via benefits on cardiac metabolism (FIGHT [Functional Impact of GLP-1 for Heart Failure Treatment; NCT01800968]). Despite metformin's package label warning about its use in patients with HF, the occurrence of lactic acidosis is exceedingly low in clinical practice, and recent observational data (77) suggest possible benefits on clinical outcomes associated with its use in HF. Ongoing large-scale diabetes studies investigating cardiovascular outcomes, including HF, will inform the management of DM in these patients (EXSCEL [Exenatide Study of Cardiovascular Event Lowering Trial; NCT01144338]). Pending the results of these studies, the treatment of DM in patients with HF should preferentially include agents with favorable safety profiles in patients with cardiovascular disease (78). Given the key roles of obesity and metabolic syndrome in the underlying pathophysiology (79), they may also represent important targets in DM patients with HF, particularly those with HFpEF.

**Renal dysfunction.** Registry data indicate a similar extent of renal insufficiency in HF patients across the EF spectrum (2,11). The reports vary significantly in different datasets, depending on the specific criteria used, but the figures are similar in patients with HFpEF and HFrEF. The interdependence of heart and kidney dysfunction is captured by the recently described “cardiorenal syndrome” (7,80). Renal dysfunction may worsen HF through multiple mechanisms, including increased sodium and fluid retention, anemia, inflammation, and uremic toxins, as well as RAAS and sympathetic activation. A recent analysis found a significant association between urinary markers of renal dysfunction and the risk for new-onset HFpEF but not HFrEF (81). Conversely, HF may lead to renal dysfunction and cardiorenal syndrome through mechanisms related to low cardiac output, accelerated atherosclerosis, inflammation, and increased venous pressure. The multitude of mechanisms that may result in renal dysfunction could, in part, explain its similar prevalence in HFpEF and HFrEF patients. For instance, HFpEF patients may be more likely to have underlying renal dysfunction related to diabetic nephropathy, whereas atherosclerosis may contribute to renal function changes in patients with HFrEF due to ischemic/nephrosclerotic etiology (16).

Renal dysfunction is an established risk factor for adverse events in patients with HF (82,83). ADHERE (Acute Decompensated Heart Failure National Registry) revealed that more than one-half of acute HF patients had at least moderate renal insufficiency on admission, which was associated with increased mortality (84). Importantly, recent data have demonstrated that the association between renal dysfunction and poor outcomes is complex. For instance, transient worsening renal function during acute HF hospitalization may not affect post-discharge outcomes (85,86), and aggressive fluid removal leading to hemoconcentration may be associated with lower mortality, despite evidence of worsening renal function (86). Thus, the underlying cause and trajectory of renal dysfunction could play a role in determining the impact on subsequent outcomes. Notably, HF patients with renal dysfunction tend to be older, with lower blood pressure and higher plasma B-type natriuretic peptide levels (87). Kidney disease also affects guideline-directed medical therapy in HFrEF patients due to concerns about worsening glomerular filtration rate and hyperkalemia (87). In addition to similar prevalence in HFrEF and HFpEF patients, the increased risk associated with the comorbidity is similar in both patient groups. Ather et al. (24) demonstrated that renal

insufficiency was associated with an ~25% to 30% increase in mortality. In a community-based HF patient cohort, worsening estimated glomerular filtration rate was associated with a graded increase in the risk for death and hospitalization, with similar findings in those with HFpEF and HFrEF (30).

The implications of renal insufficiency for the treatment of HFpEF and HFrEF patients are several-fold. First, despite concerns related to hyperkalemia, therapies such as angiotensin-converting enzyme inhibitors should be initiated and monitored in accordance with current guidelines (88,89). Recent data suggest that worsening renal function while on an RAAS inhibitor has a better prognosis than with placebo, suggesting that a RAAS inhibitor should not necessarily be discontinued in patients who develop worsening renal function (90). Renal insufficiency may also have important implications related to the management of volume status and the titration of diuretic therapies. For instance, with more severe underlying renal disease, it may be necessary to consider alternative loop diuretic agents, such as torsemide, or the addition of a thiazide diuretic agent (91).

**Sleep-disordered breathing.** In recent years, the prevalence and impact of SDB in HF patients have been increasingly recognized, and multiple ongoing registries are collecting data in this regard (SchlaHF [Sleep-Disordered Breathing in Heart Failure—The SchlaHF-Registry; NCT01500759]). Previous studies have found that SDB is prevalent in both those with HFpEF and those with HFrEF, occurring in upward of 50% to 80% of patients (92-94). Two primary types of SDB occur and may coexist in HF patients: obstructive sleep apnea (OSA) and central sleep apnea (CSA). HFpEF patients tend to more often have OSA, compared with HFrEF patients who tend to have CSA to a greater extent (95). Women with HF are less likely to have SDB compared with men, and its severity may be lower (96). Risk factors for the development of both types of SDB in HF patients include male sex and increased age (97,98). Elevated body mass index is an additional risk factor for OSA, whereas severe LV impairment and atrial fibrillation increase the likelihood of CSA (97,99). SDB is proinflammatory, with effects on oxidative stress and sympathetic activation (94).

SDB has been associated with increased morbidity and mortality in the general population (100-102); however, its impact on HF patient outcomes is less well defined. The majority of studies in HF patients focused on HFrEF patients, who had SDB that was an independent predictor of cardiac readmission (103). In 164 patients with chronic stable HFrEF, untreated

**TABLE 2** Treatments for Comorbidities in Patients With HFpEF and Those With HFrEF

Recommendations/Comments	
Chronic obstructive pulmonary disease	<p>Emphasis on prevention (e.g., vaccinations, smoking cessation)</p> <p>Consider preferential use of inhaled anticholinergics over beta-agonists pending definitive clinical trials</p> <p>Early intervention in the setting of exacerbations of either disease</p> <p>Multidisciplinary management with cardiology and pulmonary</p> <p>Volume optimization may be particularly important in these patients</p> <p>Preferential use of cardioselective beta-blockers (metoprolol succinate or bisoprolol) pending additional prospective trials</p>
Anemia	<p>Thorough evaluation and treatment of underlying cause(s) of anemia</p> <p>Management of contributing factors such as renal insufficiency and diabetes</p> <p>Broad application of erythropoietin-stimulating agents in HFrEF is not supported by previous studies</p> <p>Iron deficiency may represent a relevant treatment target</p>
Diabetes mellitus	<p>Avoid diabetic therapies that have been associated with increased risk of heart failure (e.g., TZDs, DPP-4 inhibitors)</p> <p>Careful monitoring for other diabetic agents (e.g., metformin) in the setting of heart failure decompensation and renal dysfunction</p> <p>Preferential use of metformin may be reasonable pending prospective trials given observational data suggesting benefits for clinical outcomes</p>
Renal dysfunction	<p>Appropriate initiation of ACE inhibitors/ARBs and MRAs, as able, with careful clinical monitoring</p> <p>Volume status may be a key target of intervention</p> <p>Alternative loop diuretic agents (e.g., torsemide) may be indicated</p> <p>Multidisciplinary management with cardiology and nephrology</p>
Sleep-disordered breathing	<p>CPAP or ASV device therapy may provide benefits on clinical status (outcomes benefit undefined)</p>

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ASV = adaptive servo-ventilation; COPD = chronic obstructive pulmonary disease; CPAP = continuous positive airway pressure; DPP-4 = dipeptidyl peptidase 4; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; TZDs = thiazolidinediones.

OSA was associated with increased mortality on multivariable analysis (104). CSA was also shown to be a predictor of mortality in HFrEF (105). However, not all studies demonstrated a relationship between SDB and outcomes in HFrEF patients (106,107).

To our knowledge, no previous studies scrutinized a differential association between SDB and outcomes in HFrEF versus HFpEF patients. Studies to date in HFpEF patients generally assessed <200 patients, with the emphasis on describing prevalence and patient characteristics, rather than outcomes (95,108). Thus, future research is needed to explore the impact of SDB on outcomes in HFpEF. SDB may represent a particularly important comorbidity in HFpEF patients, given the high prevalence of obesity in this patient population.

The primary treatment for OSA is nocturnal continuous positive airway pressure (CPAP). Although observational studies in HF patients with OSA suggested potential benefits with CPAP on clinical outcomes (109), large-scale randomized studies are needed. The role of CPAP in CSA is even less well defined. The largest randomized, prospective study

of HF patients with CSA (N = 258) found no survival benefit with CPAP, despite improvements in EF and functional status (110). Compared with CPAP devices, minute ventilation-targeted adaptive servo-ventilation may treat both CSA and OSA with improved tolerability. Studies have demonstrated benefits on surrogate endpoints with adaptive servo-ventilation in HF patients (111,112). Survival benefits with adaptive servo-ventilation in HF patients have not been demonstrated, and randomized trials are ongoing (SERVE-HF [Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure; NCT00733343] and CAT-HF [Cardiovascular Improvements With MV ASV Therapy in Heart Failure; NCT01953874]).

**OTHER COMORBIDITIES.** Obesity is common in the general HF population, with a higher prevalence in HFpEF patients (Table 1). Although increased body weight has been associated with improved outcomes in cardiovascular disease populations (113), recent reports discussed a balanced reappraisal of this obesity paradox (114,115). A higher weight may be associated with better outcomes compared with HF patients with cardiac cachexia and/or nutritional deficiencies. Potential mechanisms for improved outcomes associated with obesity include increased metabolic reserve and lipoprotein pools to serve as scavengers for circulating endotoxins. However, the associations between obesity and metabolic syndrome, glucose intolerance, and diabetes are likely to explain, in part, the link between increased body weight and adverse events in certain circumstances. For instance, a recent study in 4,109 HFpEF patients found a U-shaped relationship between body mass index and adverse clinical events. Body mass indices <23.5 or  $\geq 35$  kg/m<sup>2</sup> were each associated with a 27% increase in death or cardiovascular hospitalization, compared with the reference group body mass index of 26.5 to 30.9 kg/m<sup>2</sup> (116). Future studies are needed to assess whether treatment strategies targeting appropriate weight gain or weight reduction can improve outcomes in both HFpEF and HFrEF patients.


Additional important comorbidities in HF patients include frailty and arthritis (117). Frailty, limited mobility, and fall risk are increasingly recognized as important predictors of outcomes in HF patients (118). Osteoarthritis is of particular interest, given the inflammatory hypothesis linking comorbidities and adverse cardiovascular outcomes (119). Furthermore, nonsteroidal anti-inflammatory drug treatment for osteoarthritis may have direct consequences on fluid retention and the precipitation of acute HF. There is a need for future research on these topics as well as on



depression, myopathy, and liver disease, with respect to implications for the management and outcomes of HFpEF and HFrEF patients.

**CLINICAL PRACTICE AND IMPLICATIONS FOR FUTURE TRIAL DESIGN.** Although the presence of multiple comorbid diseases is almost universal in clinical practice, HF guidelines provide little discussion of this, and the evidence base is sparse and mostly observational. Compared with HFrEF patients, those with HFpEF tend to have an increased burden of COPD, DM, and anemia, which are associated with increased morbidity and mortality. Because the development of novel HF therapies has slowed in recent years, and most contemporary HF trials have

failed to improve outcomes above standard medical therapy (120,121), we suggest the need for a critical reappraisal of treatment strategies in HF in which clinicians target comorbidities, in addition to targeting the underlying cardiac dysfunction (Table 2). This approach may be particularly relevant for HFpEF patients for whom no therapies are available to reduce the substantial morbidity and mortality. In addition, on the basis of the recent data discussed earlier, improved management of specific comorbidities in HFpEF patients may have an even greater impact than in HFrEF. Most studies to date targeting comorbidities in HF patients have focused on the HFrEF population, with few interventions on comorbidities empirically



evaluated in HFpEF patients. Given that many of these conditions are closely interrelated and may potentiate each other, targeting comorbidities may represent an important component in the comprehensive management of HF patients.

Another major clinical implication of these data relates to polypharmacy, particularly in the elderly, in whom the prevalence of HF rises sharply. Elderly patients may exhibit variable responses to standard medical HF therapy and are also more prone to experience adverse effects. Because the elderly also have more comorbidities requiring specific therapies, polypharmacy is commonplace. Medications with opposing actions may be used simultaneously (e.g., inhaled beta-agonists, beta-blockers) such that medications for non-HF comorbidities may exacerbate HF and vice versa. In general, polypharmacy increases the potential for drug interactions and reduces patients' compliance. Moreover, frailty and cognitive impairment are more common among elderly HF patients and represent additional risks for nonadherence.

Data on the specific role of polypharmacy in HFrEF versus HFpEF are lacking. Given the greater burden of comorbidities in HFpEF, it is reasonable to assume, however, that the negative impact of polypharmacy is at least as great in HFpEF compared with HFrEF. At the same time, HF trials that established morbidity and mortality benefits were predominantly executed in nonelderly cohorts. Assumption of similar efficacy in geriatric populations is mostly on the basis of extrapolation of these data, but the true risk-benefit ratio may be less favorable.

These observations also may have important implications for future HF trial design. As the clinical trial landscape transitions toward more pragmatic trials with broad entry criteria, in some circumstances, study populations may (and perhaps, should) increasingly include those with multiple comorbid diseases. Noncardiologists managing HF patients cite comorbidity and lack of generalizability of previous trials to comorbid patients as a "reason" for not applying standard therapies. Improved generalizability of trial results could translate into increased uptake of evidence-based treatments for both HF and

comorbid diseases. Although this approach may be possible in HFrEF, given the heterogeneity of the patient population, broad entry criteria for trials in HFpEF might be more likely to fail. Strategies to promote success include use of natriuretic peptide levels for entry criteria, as highlighted by the results of the recent TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) study (122). Importantly, data suggest that the use of different threshold levels for natriuretic peptides may be appropriate in HFrEF versus HFpEF patients, as well as in those with obesity and renal dysfunction (123). Considerations for trial design related to comorbidities are summarized in **Figure 1**. Importantly, the inclusion of patients with comorbidities in clinical trials may require intensified monitoring and safety evaluations. For instance, there are notable comorbidity-specific adverse effects associated with certain medications (e.g., hyperkalemia with RAAS inhibition in renal dysfunction patients). Finally, given the recent lack of success in HF clinical trials using add-on HF-directed therapies (e.g., direct renin inhibitors [124]), another potential trial approach is to specifically target underlying comorbidities to improve overall patient outcomes.

## CONCLUSIONS

Compared with HFrEF, patients with HFpEF have an increased burden of COPD, DM, anemia, and obesity but a similarly high prevalence of renal disease and SDB. In general, the increased risk for morbidity and mortality associated with these comorbidities is similar in those with HFpEF and HFrEF. Careful attention to the diagnosis and management of specific comorbidities in HF patients may help to improve patient outcomes, but further observational and interventional research is urgently required, particularly as noncardiac comorbidity is almost universal in the typical HF population.

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. Robert J. Mentz, Duke University Medical Center, 2301 Erwin Road, Durham, North Carolina 27710. E-mail: [robert.mentz@duke.edu](mailto:robert.mentz@duke.edu).

## REFERENCES

1. Mentz RJ, Felker GM. Noncardiac comorbidities and acute heart failure patients. *Heart Fail Clin* 2013;9:359-67, vii.
2. Yancy CW, Lopatin M, Stevenson LW, et al., for the ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. *J Am Coll Cardiol* 2006;47:76-84.
3. Centers for Medicare & Medicaid Services. Chronic Conditions Among Medicare Beneficiaries. Chartbook, 2012 Edition. Baltimore, MD: Centers for Medicare & Medicaid Services, 2012.
4. van Deursen VM, Urso R, Laroche C, et al. Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. *Eur J Heart Fail* 2014;16:103-11.
5. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. *Eur J Heart Fail* 2009;11:130-9.

6. Mentz RJ, Fiuzat M, Wojdyla DM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. *Eur J Heart Fail* 2012;14:395-403.
7. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. *J Am Coll Cardiol* 2008;52:1527-39.
8. Mentz RJ, Lewis EF. Epidemiology of cardiorenal syndrome. *Heart Fail Clin* 2010;6:333-46.
9. Lau YC, Lane DA, Lip GY. Atrial fibrillation and heart failure: a bad combination. *Am J Cardiol* 2014;113:1196-7.
10. Fonarow GC, Stough WG, Abraham WT, et al., for the OPTIMIZE-HF Investigators. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. *J Am Coll Cardiol* 2007;50:768-77.
11. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. *Circulation* 2012;126:65-75.
12. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. *JAMA* 2006;296:2209-16.
13. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med* 2006;355:251-9.
14. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe: Part 1: patient characteristics and diagnosis. *Eur Heart J* 2003;24:442-63.
15. Nieminen MS, Brutsaert D, Dickstein K, et al., for the EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J* 2006;27:2725-36.
16. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. *J Am Coll Cardiol* 2004;43:317-27.
17. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. *Circulation* 2009;119:3070-7.
18. Ho JE, Lyass A, Lee DS, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. *Circ Heart Fail* 2013;6:279-86.
19. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. *Am J Cardiol* 1993;72:310-3.
20. Klappholz M, Maurer M, Lowe AM, et al., for the New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. *J Am Coll Cardiol* 2004;43:1432-8.
21. Senni M, Redfield MM. Heart failure with preserved systolic function: a different natural history? *J Am Coll Cardiol* 2001;38:1277-82.
22. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. *N Engl J Med* 2006;355:260-9.
23. van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. *J Am Coll Cardiol* 2013;61:1498-506.
24. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *J Am Coll Cardiol* 2012;59:998-1005.
25. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. *J Am Coll Cardiol* 2003;42:1226-33.
26. Campbell RT, Jhund PS, Castagno D, et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? *J Am Coll Cardiol* 2012;60:2349-56.
27. Mohammed SF, Borlaug BA, Roger VL, et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. *Circ Heart Fail* 2012;5:710-9.
28. Felker GM, Shaw LK, Stough WG, et al. Anemia in patients with heart failure and preserved systolic function. *Am Heart J* 2006;151:457-62.
29. MacDonald MR, Petrie MC, Varyani F, et al., for the CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme. *Eur Heart J* 2008;29:1377-85.
30. Smith DH, Thorp ML, Gurwitz JH, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. *Circ Cardiovasc Qual Outcomes* 2013;6:333-42.
31. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013;62:263-71.
32. Smith BM, Prince MR, Hoffman EA, et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. *Chest* 2013;144:1143-51.
33. Mentz RJ, Fiuzat M, Kraft M, et al. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? *J Cardiac Fail* 2012;18:413-22.
34. Caruana L, Petrie MC, Davie AP, et al. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. *BMJ* 2000;321:215-8.
35. Mentz RJ, Schmidt PH, Kwasny MJ, et al. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. *J Card Fail* 2012;18:515-23.
36. Mentz RJ, Schulte PJ, Fleg JL, et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). *Am Heart J* 2013;165:193-9.
37. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. *J Am Coll Cardiol* 2011;57:2127-38.
38. Dungen HD, Apostolovic S, Inkrot S, et al., for the CIBIS-ELD Investigators and Project Multi-centre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. *Eur J Heart Fail* 2011;13:670-80.
39. Berry C, Hogg K, Norrie J, et al. Heart failure with preserved left ventricular systolic function: a hospital cohort study. *Heart* 2005;91:907-13.
40. Lam CS, Lyass A, Kraigher-Krainer E, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. *Circulation* 2011;124:24-30.
41. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med* 2010;362:217-27.
42. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. *J Am Coll Cardiol* 2010;55:1780-7.
43. Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. *Respir Med* 2011;105 Suppl 1:S44-9.
44. Mentz RJ, Wojdyla D, Fiuzat M, et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). *Am J Cardiol* 2013;111:582-7.
45. Hsich EM, Grau-Sepulveda MV, Hernandez AF, et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. *Am Heart J* 2012;163:430-7.e3.
46. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). *Am J Cardiol* 2008;101:223-30.
47. O'Meara E, Clayton T, McEntegart MB, et al., for the CHARM Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure:

Assessment of Reduction in Mortality and Morbidity (CHARM) Program. *Circulation* 2006;113:986-94.

48. Anand IS. Anemia and chronic heart failure: implications and treatment options. *J Am Coll Cardiol* 2008;52:501-11.

49. Anand IS, Chandrasekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. *Br Heart J* 1993;70:357-62.

50. Anand IS, Chandrasekhar Y, Wander GS, et al. Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. *J Am Coll Cardiol* 1995;25:1402-7.

51. Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. *Circulation* 1994;90:12-6.

52. Lindendorf J. Prevalence of anemia and effects on mortality in patients with heart failure. *Am Heart J* 2005;149:391-401.

53. Groenewald HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. *J Am Coll Cardiol* 2008;52:818-27.

54. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. *Heart Fail Rev* 2008;13:387-92.

55. van der Meer P, Groenewald HF, Januzzi JL Jr, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. *Heart* 2009;95:1309-14.

56. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. *Circulation* 2004;110:149-54.

57. Scrutinio D, Passantino A, Santoro D, et al. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. *Eur J Heart Fail* 2011;13:61-7.

58. von Haehling S, van Veldhuisen DJ, Roughton M, et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. *Eur J Heart Fail* 2011;13:656-63.

59. Swedberg K, Young JB, Anand IS, et al., for the RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med* 2013;368:1210-9.

60. Anker SD, Comin Colet J, Filippatos G, et al., for the FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009;361:2436-48.

61. Comin-Colet J, Enjuanes C, González G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. *Eur J Heart Fail* 2013;15:1164-72.

62. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. *Am Heart J* 2013;165:575-82.e3.

63. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. *Circulation* 2007;115:3213-23.

64. Aneja A, Tang WH, Bansal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. *Am J Med* 2008;121:748-57.

65. Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. *J Am Coll Cardiol* 2001;37:1943-9.

66. Schannwell CM, Schneppenheim M, Perings S, et al. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. *Cardiology* 2002;98:33-9.

67. Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. *Diabetes Metab* 1997;23:213-8.

68. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. *J Am Coll Cardiol* 1997;30:527-32.

69. Dhinra R, Vasan RS. Diabetes and the risk of heart failure. *Heart Fail Clin* 2012;8:125-33.

70. De Groote P, Lamblin N, Mouquet F, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. *Eur Heart J* 2004;25:656-62.

71. Harjola VP, Follath F, Nieminen MS, et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. *Eur J Heart Fail* 2010;12:239-48.

72. Parissis JT, Rafouli-Stergiou P, Mebazaa A, et al. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. *Int J Cardiol* 2012;157:108-13.

73. Greenberg BH, Abraham WT, Albert NM, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2007;154:277.e1-8.

74. Sarma S, Mentz RJ, Kwasny MJ, et al., for the EVEREST Investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. *Eur J Heart Fail* 2013;15:194-202.

75. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. *Eur Heart J* 2010;31:824-31.

76. Scirica BM, Bhatt DL, Braunwald E, et al., for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013;369:1317-26.

77. Weir DL, McAlister FA, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. *J Am Coll Cardiol HF* 2014;2:573-82.

78. American Diabetes Association. Standards of medical care in diabetes-2013. *Diabetes Care* 2013;36 Suppl 1:S11-66.

79. van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. *Circulation* 2012;126:830-9.

80. Waldum B, Os I. The cardiorenal syndrome: what the cardiologist needs to know. *Cardiology* 2013;126:175-86.

81. Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. *Eur Heart J* 2013;34:1424-31.

82. Hillege HL, Nitsch D, Pfeffer MA, et al., for the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. *Circulation* 2006;113:671-8.

83. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. *J Am Coll Cardiol* 2000;35:681-9.

84. Heywood JT, Fonarow GC, Costanzo MR, et al., for the ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. *J Card Fail* 2007;13:422-30.

85. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. *J Card Fail* 2010;16:541-7.

86. Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. *Circulation* 2010;122:265-72.

87. Blair JE, Pang PS, Schrier RW, et al., for the EVEREST Investigators. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. *Eur Heart J* 2011;32:2563-72.

88. Yancy CW, Jessup M, Bozkurt B, et al., for the American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;62:e147-239.

89. McMurray JJ, Adamopoulos S, Anker SD, et al., for the ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012;33:1787-847.

90. Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. *Eur J Heart Fail* 2014;16:41-8.
91. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. *J Am Coll Cardiol* 2012;59:2145-53.
92. Bitter T, Faber L, Hering D, et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. *Eur J Heart Fail* 2009;11:602-8.
93. Chan J, Sanderson J, Chan W, et al. Prevalence of sleep-disordered breathing in diastolic heart failure. *Chest* 1997;111:1488-93.
94. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. *J Am Coll Cardiol* 2011;57:119-27.
95. Herrscher TE, Akre H, Overland B, et al. High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function. *J Card Fail* 2011;17:420-5.
96. Paulino A, Damy T, Margarit L, et al. Prevalence of sleep-disordered breathing in a 316-patient French cohort of stable congestive heart failure. *Arch Cardiovasc Dis* 2009;102:169-75.
97. Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. *Am J Respir Crit Care Med* 1999;160:1101-6.
98. Bradley TD, Floras JS. Sleep apnea and heart failure: part I: obstructive sleep apnea. *Circulation* 2003;107:1671-8.
99. Ferrier K, Campbell A, Yee B, et al. Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure. *Chest* 2005;128:2116-22.
100. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005;365:1046-53.
101. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med* 2009;6:e1000132.
102. Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. *J Am Coll Cardiol* 2013;62:610-6.
103. Khayat R, Abraham W, Patt B, et al. Central sleep apnea is a predictor of cardiac readmission in hospitalized patients with systolic heart failure. *J Card Fail* 2012;18:534-40.
104. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. *J Am Coll Cardiol* 2007;49:1625-31.
105. Javaheiri S, Shukla R, Zeigler H, et al. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. *J Am Coll Cardiol* 2007;49:2028-34.
106. Yumino D, Wang H, Floras JS, et al. Relationship between sleep apnoea and mortality in patients with ischaemic heart failure. *Heart* 2009;95:819-24.
107. Roebuck T, Solin P, Kaye DM, et al. Increased long-term mortality in heart failure due to sleep apnoea is not yet proven. *Eur Respir J* 2004;23:735-40.
108. Sekizuka H, Osada N, Miyake F. Sleep disordered breathing in heart failure patients with reduced versus preserved ejection fraction. *Heart Lung Circ* 2013;22:104-9.
109. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. *J Am Coll Cardiol* 2011;57:119-27.
110. Bradley TD, Logan AG, Kimoff RJ, et al., for the CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. *N Engl J Med* 2005;353:2025-33.
111. Sharma BK, Bakker JP, McSharry DG, et al. Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a systematic review and meta-analysis. *Chest* 2012;142:1211-21.
112. Pepperell JC, Maskell NA, Jones DR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. *Am J Respir Crit Care Med* 2003;168:1109-14.
113. Lavie CJ, McAuley PA, Church TS, et al. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. *J Am Coll Cardiol* 2014;63:1345-54.
114. Doehner W. Critical appraisal of the obesity paradox in cardiovascular disease: How to manage patients with overweight in heart failure? *Heart Fail Rev* 2014;19:637-44.
115. Gaddam KK, Ventura HO, Lavie CJ. Metabolic syndrome and heart failure—the risk, paradox, and treatment. *Curr Hypertens Rep* 2011;13:142-8.
116. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial. *Circ Heart Fail* 2011;4:324-31.
117. Afllalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol* 2014;63:747-62.
118. McNallan SM, Singh M, Chamberlain AM, et al. Frailty and healthcare utilization among patients with heart failure in the community. *J Am Coll Cardiol HF* 2013;1:135-41.
119. Rahman MM, Kopec JA, Cibere J, et al. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. *BMJ Open* 2013;3:e002624.
120. Massie BM, O'Connor CM, Metra M, et al., for the PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. *N Engl J Med* 2010;363:1419-28.
121. Mentz RJ, Felker GM, Ahmad T, et al. Learning from recent trials and shaping the future of acute heart failure trials. *Am Heart J* 2013;166:629-35.
122. Pitt B, Pfeffer MA, Assmann SF, et al., for the TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014;370:1383-92.
123. Daniels LB, Maisel AS. Natriuretic peptides. *J Am Coll Cardiol* 2007;50:2357-68.
124. Gheorghiade M, Böhm M, Greene SJ, et al., for the ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. *JAMA* 2013;309:1125-35.

---

**KEY WORDS** comorbidities, ejection fraction, heart failure

---

**APPENDIX** For the Medline (via PubMed) search strategy, please see the online version of this article.